- MindMed Has Developed New Technology That Could Help Shorten or Stop an Unwanted LSD Trip
- MindMed’s ‘LSD Neutralizer’ Could Help the Industry Reduce the Stigma and Fear Associated with Psychedelics By Eliminating ‘Bad Trip’ Experiences
MindMed (NEO: MMED) (OTC: MMEDF) (FRA: BGHM), in collaboration with the Liechti Laboratory at the University Hospital Basel, announced yesterday it discovered a new technology that the company says could help shorten or even stop the effects of an undesired LSD trip.
Based in Basel Switzerland, the Liechti Laboratory is described by MindMed as “the leading research center focused on the pharmacology of psychedelic substances.” MindMed’s newly discovered psychedelic neutralizer technology is based on the surprising results of the collaborative experimental research conducted at the Liechti Lab.
“The innovative and original work of the Liechti Laboratory is a treasure trove of novel data on LSD. We are just at the beginning of several significant discoveries that have the potential to further the application of psychedelics as therapeutic medicines. If developed, these discoveries will benefit both patients and therapists working in the psychedelic medicine space,” stated JR Rahn, co-founder and co-CEO of MindMed.
The company believes its new invention has the potential to reduce the hallucinogenic effects that certain psychedelic drugs such as LSD have been known to produce. For example, a medical patient that’s using LSD in combination with psychotherapy could benefit from having the ability to neutralize an unwelcomed psychedelic trip should one arise. The patient could then carry on with the session, rather than have to leave because they’re ‘tripping balls.’
For those unfamiliar with the term, Wikipedia describes a ‘bad trip’ as: “a frightening and unpleasant experience triggered by psychoactive drugs, especially psychedelic drugs such as LSD and magic mushrooms.” Undesired effects produced during a bad trip can include a range of feelings, which include mild anxiety, alienation, abject terror, ultimate entrapment, or complete loss of self-identity.
Once developed further, the company thinks its technology could one day act as an “off-switch to an LSD trip.” Although bad trips are a rare occurrence, the fear of encountering one and the stigma associated with it remains. MindMed plans to provide the medical professionals and therapists responsible for dosing LSD in a clinical setting with the technology and resources to better control the effects of the psychedelic drug. If MindMed’s technology is successful, it has the ability to significantly improve the patient experience and outcome as well as reduce the fear and stigma some associate with psychedelic medicine.
MindMed also reported that it filed a patent application in the United States for the company’s neutralizer technology. The company gained the exclusive, worldwide rights to the technology as covered by the recently filed patent application, which was based on the inventions previously generated by the Liechti Laboratory in LSD and any future LSD research funded by MindMed. The company is developing a robust patent library of psychedelics-based technologies, which now includes its new LSD neutralizer.
“MindMed believes that true innovations will always be protectable, which is why MindMed is committed to investing in novel research and proprietary data around LSD and other psychedelics. We believe this latest invention is a good example of the work we will seek to patent and we remain committed to understanding how pharmaceutical ingredients, novel methods of manufacture, new uses of older medications, proprietary formulations and surprising experimental results can benefit patients,” said MindMed co-founder and co-CEO Stephen Hurst.
MMED Stock Price Action & Chart
Shares of MindMed’s NEO listed MMED stock closed today at $0.68 per share, up 4.6% on the day. The company’s U.S. OTC Markets listed MMEDF stock closed today’s trading session up 8.2% at $0.49 per share. Overseas in Germany, MindMed’s Frankfurt listed stock also had a big day with shares trading up 12.47% to close at $0.46.
Learn more about MindMed: Website | IR Website | Investor Deck | MMED Chart
Also Read: These 2 Companies Are Turning LSD, Magic Mushrooms, Ketamine and MDMA into the Next Blockbuster Drugs
Canopy Growth Founder Bruce Linton and Billionaire “Mr. Wonderful” Kevin O’Leary from Shark Tank, Are Going All in on What They Think is a Much Bigger Opportunity Than the Cannabis Boom
Read More Psychedelic Profits Articles Here
Follow Psychedelic Profits on Social Media: Facebook | Twitter | LinkedIn | Investor Group
Did you enjoy this article? If so, sign up for our Email Newsletter below to start receiving our weekly recap of the week’s best articles.
The Most Anticipated U.S. MSO IPO of 2020 is Drawing Near
The Cannabis Sector is Long Overdue for a High-Profile IPO
The Wait is Nearly Over, TCI’s MSO IPO of 2020 is Almost Here
Get Your Copy of The Ultimate Cannabis Investing Guide
Join the Discussion in the TCI Investor Group
Disclosure: The Cannabis Investor does not hold a position in any of the stocks mentioned in this article.
Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos